moxifloxacin has been researched along with nocodazole in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (nocodazole) | Trials (nocodazole) | Recent Studies (post-2010) (nocodazole) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 3,078 | 0 | 655 |
| Protein | Taxonomy | moxifloxacin (IC50) | nocodazole (IC50) |
|---|---|---|---|
| Chain A, Glutathione-requiring prostaglandin D synthase | Homo sapiens (human) | 65 | |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.8334 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.64 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.3775 | |
| Tubulin beta chain | Sus scrofa (pig) | 0.76 | |
| Tubulin beta-4A chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta chain | Homo sapiens (human) | 1.2975 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 1.2975 | |
| Adenosine receptor A2a | Homo sapiens (human) | 7.509 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 1.2975 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 1.2975 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 6.232 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 2.3 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 1.2975 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 1.2975 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.3 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.3 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 1.2975 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 1.2975 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beuerman, RW; Chalasani, MLS; Iyer, A; Lakshminarayanan, R; Leng Goh, ET; Lloyd, DG; Madder, A; Mayandi, V; Parmar, A; Prior, SH; Singh, I; Taylor, EJ; Verma, NK | 1 |
1 other study(ies) available for moxifloxacin and nocodazole
| Article | Year |
|---|---|
Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo.
Topics: Animals; Depsipeptides; Drug Design; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Methicillin-Resistant Staphylococcus aureus; Mice; Staphylococcal Infections; Staphylococcus aureus; Vancomycin Resistance; Vancomycin-Resistant Enterococci | 2018 |